Evidence-Based Complementary and Alternative Medicine / 2018 / Article / Fig 6

Research Article

Aster glehni Extract Containing Caffeoylquinic Compounds Protects Human Keratinocytes through the TRPV4-PPARδ-AMPK Pathway

Figure 6

Western blot analyses and RT-PCR for TRPV4, AMPK, and PPAR in HaCaT cells treated with antagonists or siRNAs for TRPV4, PPAR, and AMPK. RT-PCR for TRPV4, AMPK, and PPAR in HaCaT cells treated with TRPV4 antagonist in pathological conditions. TRPV4 antagonist and siRNA decreased the protein levels of TRPV4, PPARδ, and AMPK (a, d). PPARδ antagonist and siRNA decreased the protein levels PPARδ and AMPK (b, d). AMPK antagonist and siRNA decreased only AMPK (c, d). In pathological conditions, the TRPV4 antagonist reversed the AG effects on TRPV4, PPARδ, and AMPK (e). The results are expressed as means ± SEM. N=3 for each group. Values were statistically analyzed by unpaired t-test and one-way ANOVA. All experiments were repeated over three times. The dash-dotted line means the one-way ANOVA result between ctrl and all other groups. The dotted line means the one-way ANOVA result among groups except for control. Meaning of indications: Ctrl is an untreated control group, DNCB is a DNCB treated group, D+AG is a DNCB+AG treated group, D+A+Ta is a DNCB+AG+TRPV4 antagonist treated group, SDS is a SDS-treated group, S+AG is a SDS+AG treated group, and S+A+Ta is a SDS+AG+TRPV4 antagonist treated group.
(a)
(b)
(c)
(d)
(e)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.